MedTrace Logo

Impact of Alirocumab on Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease But Without Prior Ischemic Events

NCT07734753 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 4006

Last updated 2026-07-29

No results posted yet for this study

Summary

To estimate ischemic event rates in individuals with established atherosclerotic cardiovascular disease (ASCVD) and no prior acute ischemic events, comparing alirocumab with no Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor therapy, using a target trial emulation of routine clinical practice data.

Conditions

  • Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events

Interventions

DRUG

Alirocumab

The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.

DRUG

Comparator: No PCSK9i Therapy (monoclonal antibodies or small interfering RNA agents)

The study will not administer any treatment, only observe the treatment as prescribed in routine clinical practice.

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-15
Primary Completion
2026-05-15
Completion
2026-08-15
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07734753 on ClinicalTrials.gov